LSB

25-NSE - LakeShore Biopharma Co., Ltd. (0001946399) (Subject)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, September 22, 2025, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq"). On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC Market") under the symbols "LSBCF" and "LSBWF", res

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), dated September 11, 2025, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") because the closing bid price for the Company's ordinary shares was below $1.00 per share for 30 consecutive business days. Furt

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB, ", LakeShore Biopharma", or the ", Company", )), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the independent special committee (the "Special Committee") of the Company's board of directors (the "Board"), formed to evaluate and consider the previously announced revised preliminary non-binding proposal letter dated August 26, 2025 (the "Proposal"), has retained Kroll, LLC as its financial advisor, Gibson, Dunn & Crutcher LLP as its U.S. legal cou

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium (the "Consortium") comprised of Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (together, "Oceanpine Capital"), and Crystal Peak Investment Inc. to acquire all of the outstandin

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter (the "Proposal Letter"), dated August 18, 2025, from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (collectively, "Oceanpine Capital") to acquire all of the outstanding ordinary shares, par value US$0.0002 per share, of the Company (the "Ordinary Shares") th

Total revenue reached RMB615.0 million, representing 7.2% year-over-year growthGross profit rose to RMB507.2 million, up 11.3% year-over-yearGross margin improved to 82.5% from 79.5% in Fiscal Year 2024Total operating expenses decreased 34.2% year-over-year to RMB593.5 millionEBITDA[1] and Adjusted EBITDA[2] were RMB(48.5 million) and RMB0.6 million, respectively, compared to RMB(368.7 million) and RMB(236.4 million) in Fiscal Year 2024Net loss narrowed to RMB100.0 million, with an adjusted net loss[3] of RMB40.0 million, compared to RMB433.5 million and RMB266.3 million, respectively, in Fiscal Year 2024BEIJING, July 31, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeS

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

20-F - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

BEIJING, July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share and warrant purchase agreement (the "Purchase Agreement") with an institutional investor for the issuance and sale of 16,987,542 ordinary shares of the Company, par value US$0.0002 per share, at US$0.883 per share, and 16,987,542 warrants, each entitling the institutional investor to purchase one ordinary share at an exercise price of US$1.079 at any time and

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province. Approved for lot release by regulatory authorities on April 15, 2025, the new formulation will begin nationwide distribution in China within weeks, addressing critical safety challenges in vaccine administration. To address pain points such as compounding c

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

S-8 POS - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)

6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)